HKSE - Delayed Quote HKD

Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276.HK)

50.300 -0.400 (-0.79%)

As of 2:56:09 PM GMT+8. Market Open.

From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment

PR Newswire 5d ago

600276.SS

1276.HK
-0.79%
Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

PR Newswire 12d ago

1276.HK
-0.79%
600276.SS
Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal

Investing.com 1mo ago

600276.SS

NVO

^HSI
Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596

PR Newswire 1mo ago

600276.SS

1276.HK
-0.79%
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease

Business Wire 4mo ago

600276.SS

1276.HK
-0.79%
Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026

PR Newswire 5d ago

600276.SS
Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular Carcinoma

GlobeNewswire 18d ago

028300.KQ

600276.SS
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

GlobeNewswire 1mo ago

KLRA

600276.SS
Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?

Zacks 1mo ago

600276.SS

LLY

GPCR
Top China Biopharma Stocks to Watch, According to Bernstein

Investing.com 1mo ago

603259.SS

1801.HK

600276.SS
Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug

Simply Wall St. 1mo ago

NVO

600276.SS
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill

BioPharma Dive 1mo ago

600276.SS

LLY

U.S. markets open in 6h 59m

Jiangsu Hengrui Pharmaceuticals Co.,Ltd (1276.HK)

From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment

Hengrui Pharma Previews ESMO Congress 2026: 64 Research Findings Highlight Continued Progress Across Innovative Pipelines to Advance Clinical Value

Hengrui Pharma shares rise as Novo Nordisk signs $2.6 billion drug deal

Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596

Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease

Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026

Elevar Therapeutics Resubmits New Drug Application to FDA for Combination of Camrelizumab plus Rivoceranib for Use as a First-line Treatment Option for Unresectable or Metastatic Hepatocellular Carcinoma

Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting

Can Novo's Licensing Strategy Build Its Next Wave of Oral Medicines?

Top China Biopharma Stocks to Watch, According to Bernstein

Novo Nordisk (CPSE:NOVO B) Licensed A Once Weekly Oral GLP 1 GIP Drug

Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill